Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Dec 21, 2021 12:35pm

216 Views

Post# 34250951

Reovirus for the treatment of multiple myeloma

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche

Taken together, these findings demonstrate that reovirus treatment of MM cells can generate MM-specific CTLs capable of killing MM cells, even when they reside in a protective BM niche.

data suggest that induction of antitumor immunity by an OV can overcome stromal-mediated tumor resistance—a key mechanism by which MM cells escape chemotherapeutic control and give rise to relapse.

https://jitc.bmj.com/content/jitc/9/3/e001803.full.pdf

<< Previous

Bullboard Posts

Next >>

Pinnacle Silver & Gold: A promising precious metals investment